|
World Ophthalmic Pharmaceutical Market 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
This report will provide you with the following benefits, in particular: 164 seiten | |||||||||||
| Inhalt der Studie: |
Ophthalmic drugs constitute a prominent segment of the global pharmaceutical market, with sales of over $14bn in 2009. Eye diseases are common worldwide, with expanding patient populations. The recent.....
Ophthalmic drugs constitute a prominent segment of the global pharmaceutical market, with sales of over $14bn in 2009. Eye diseases are common worldwide, with expanding patient populations. The recent success of Lucentis highlighted the marked therapeutic and commercial potential of this sector. Which will be the ophthalmic blockbusters of the future? What are the most-promising R&D pipeline developments there? What are the main drivers and restraints for the market? This new report provides answers - and other essential information - to help you understand the ophthalmic pharmaceutical industry and market from 2010 onwards. World Ophthalmic Pharmaceutical Market 2010-2025 also highlights currently-untreatable and poorly-treated eye diseases with high potential for technological and commercial advances in the foreseeable future. Importantly, you will find out by how much the global ophthalmic market will expand and which countries will achieve rapid sales growth. Sales will be driven by increasing prevalence of ophthalmic disorders among aging populations worldwide. You will also find out where the most-lucrative therapeutic areas of the market will lie from 2010 to 2025. Ophthalmic market segments covered in this study include: • Glaucoma • Retinal disorder • Dry eye disorder • Ocular allergies, infections and inflammation. From 2010 onwards, novel drugs – from small-molecule anti-infectives to complex biotechnological agents – will appear. Those treatments will harness a range of drug delivery systems, with fast-emerging technology. Expected future benefits include restoration of vision and the cessation of vision loss, with high potential gains for developers. From 2010 to 2025, success in the market will be characterised by novel products with superior efficacy, safety and tolerability. World Ophthalmic Pharmaceutical Market 2010-2025 reveals how emerging technologies that increase clinical effectiveness and/or patient compliance will be particularly important therapeutically and commercially. Detailed analysis of the ophthalmic drug market World Ophthalmic Pharmaceutical Market 2010-2025 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 95 tables and figures included, as well as three full interviews with relevant authorities. You will discover a comprehensive market and industry study, one with detailed analyses and informed opinion to benefit your work. Research interviews from our detailed survey This report contains visiongain's interviews with relevant experts: • Dr Barrett Katz, MD, MBA, Chief Executive Officer and Chief Medical Officer, Danube Pharmaceuticals Inc., New York, USA • Dr Brian Levy, O.D., MSc, Chief Operating Officer, Danube Pharmaceuticals Inc., New York, USA • Dr Al Reaves, PhD, Senior Vice President of Clinical Development, Othera Pharmaceuticals Inc., Conshohocken, PA, USA • Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford and Oxford Eye Hospital, England, UK. This report shows you how the ophthalmic pharmaceutical market will develop worldwide – both technologically and commercially – from 2010 onwards. Nobody with an interest in the ophthalmic pharmaceutical market should overlook this new market study. We predict that total revenues will increase during the forecast period, 2010 to 2025. With expanding patient populations, technological advances and significant un-met needs, this sector offers high commercial potential. Do you want to harness those opportunities? You can stay ahead by ordering this report today. Report Highlights Companies Listed: Acucela Inc. Alcon, Inc. (Nestlé) Alimera Sciences Allergan, Inc. American Academy of Ophthalmology (AAO) [US] American Society of Retina Specialists (ASRS) [US] Apotex Inc. Asahi Glass Co., Ltd. AstraZeneca plc. Bausch & Lomb Inc. Bayer plc. Biovitrum AB Can-Fite BioPharma Ltd. Cerimon Pharmaceuticals, Inc. Chugai Pharmaceutical Co., Ltd. CombinatoRx Inc. CoMentis, Inc. Danube Pharmaceuticals Inc. Eli Lilly and Company Esteve USA, Inc. European Medicines Agency (EMEA) EyeGate Pharmaceuticals, Inc. Food and Drug Administration (FDA) [US] Fovea Pharmaceuticals SA. Galderma International SA (Nestlé and L'Oréal) Genentech Inc. GlaxoSmithKline plc (GSK) InSite Vision Incorporated. Inspire Pharmaceuticals, Inc. ISTA Pharmaceuticals, Inc. Kowa Company Ltd. KYORIN Pharmaceutical Co., Ltd Kyowa Hakko Kirin Co., Ltd. Laboratorios Sophia plc [Mexico] LEO Pharma Ltd. Lux Biosciences, Inc. Meda Pharmaceuticals Ltd. Merck & Co., Inc. Ministry of Health, Labour and Welfare [Japan] Moorfields Eye Hospital [UK] Mylan Inc. National Eye Institute (NEI) [US] National Institute for Health and Clinical Excellence (NICE) [UK] National Institutes of Health (NIH) [US] Neurotech USA NicOx Inc. NovaBay Pharmaceuticals, Inc. Novartis AG OPKO Health, Inc. OSI Pharmaceuticals Inc. Othera Pharmaceuticals Inc. Otsuka Pharmaceutical Co., Ltd. Pfizer Inc. pSivida Corp. QLT Inc. Quark Pharmaceuticals, Inc. Ranbaxy Laboratories Limited Regeneron Pharmaceuticals, Inc. Roche Holding AG. Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. SARcode Corporation. Senju Pharmaceuticals Co. Ltd. Sirion Therapeutics, Inc. Takeda Pharmaceuticals Co. Ltd. Targeted Genetics Corp. ThromboGenics NV. University College of London's (UCL) Institute of Ophthalmology [UK] [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Aims, Scope and Format of the Report 1.2 Research Methods 2. Ophthalmic Disorders and Treatments 2.1 The Ophthalmology Market 2.2 Ophthalmic Disorders 2.3 The Human Eye and the Vision Process 2.4 Glaucoma 2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma 2.4.2 Closed Angle Glaucoma 2.4.3 Secondary Glaucoma 2.4.4 Congenital Glaucoma 2.4.5 Normal Tension Glaucoma 2.4.6 Ocular Hypertension 2.4.7 Glaucoma Risk Factors 2.4.8 Diagnosis of Glaucoma 2.4.9 Prevalence of Glaucoma 2.4.10 Treatment of Glaucoma 2.4.11 Prostaglandins are the First-Line Treatment of Choice 2.4.12 Second-Line Glaucoma Treatments 2.4.13 Combination Treatments 2.4.14 Laser Treatment 2.4.15 Surgery (Trabeculectomy) 2.5 Age-Related Macular Degeneration (AMD) 2.5.1 Dry AMD 2.5.2 Wet AMD 2.5.3 AMD Risk Factors 2.5.4 Diagnosis of AMD 2.5.5 Prevalence of AMD 2.5.6 Treatment of AMD 2.6 Diabetic Retinopathy 2.6.1 Diagnosis of Diabetic Retinopathy 2.6.2 Prevalence of Diabetic Retinopathy 2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy 2.6.4 Pharmaceutical Treatments 2.7 Ophthalmic Allergies 2.7.1 Allergic Conjunctivitis is the Most-Common Eye Allergy 2.7.2 Ophthalmic Allergy Treatments 2.8 Ophthalmic Inflammatory Disorders 2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease 2.8.2 Ophthalmic Inflammatory Drugs 2.9 Ophthalmic Infections 2.9.1 Types of Eye Infection 2.9.2 Treatment of Eye Infections 2.10 Dry Eye Syndrome 2.10.1 Causes and Prevalence of Dry Eye Syndrome 2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears 2.10.3 Prescription-Only Drugs for Dry Eye are Limited 2.10.4 Tear Augmenters (Punctal Plugs) 3. The Global Ophthalmic Pharmaceutical Market 2010-2025 3.1 The Ophthalmic Pharmaceutical Market in 2009 3.1.1 Anti-Glaucoma had the Largest Market Share in 2009 3.1.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009 3.1.3 Three Manufacturers Account for Almost Half the Market 3.2 Global Ophthalmic Pharmaceutical Market Forecasts, 2010-2025 3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market from 2010-2016 3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2016-2025? 3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2010-2025 3.3.1 Retinal Disorders Will Power Growth from 2010-2016 3.3.2 Retinal Disorder Drug Growth Will Continue Through 2016-2020 3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma Drugs from 2020-2025? 4. The Anti-Glaucoma Market 2010-2025 4.1 The Anti-Glaucoma Market in 2009 4.1.1 Prostaglandin Analogues Led the Anti-Glaucoma Market in 2009 4.1.2 Xalatan 4.1.3 Travatan 4.1.4 Cosopt 4.1.5 Lumigan 4.1.6 Alphagan 4.1.7 Azopt 4.1.8 Xalacom 4.1.9 Trusopt 4.1.10 Combigan 4.2 Anti-Glaucoma Market Forecasts, 2010-2025 4.2.1 Generic Competition Will Impact Upon the Anti-Glaucoma Market from 2010-2016 4.2.2 Novel Anti-Glaucoma Drugs Will Drive Growth from 2010-2025 4.2.3 Xalatan Sales Forecast, 2010-2025 4.2.4 Travatan Sales Forecast, 2010-2025 4.2.5 Cosopt Sales Forecast, 2010-2025 4.2.6 Lumigan Sales Forecast, 2010-2025 4.2.7 Alphagan Sales Forecast, 2010-2025 4.2.8 Azopt Sales Forecast, 2010-2025 4.2.9 Xalacom Sales Forecast, 2010-2025 4.2.10 Trusopt Sales Forecast, 2010-2025 4.2.11 Combigan Sales Forecast, 2010-2025 5. The Ophthalmic Anti-Allergy/Inflammatory/Infective Market 2010-2025 5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2009 5.1.1 Patanol 5.1.2 Vigamox/Vegamox 5.1.3 TobraDex 5.1.4 Pataday 5.1.5 Acular 5.1.6 Cravit 5.1.7 Zymar 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2010-2025 5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline 5.2.2 Patanol Sales Forecast, 2010-2025 5.2.3 Vigamox Sales Forecast, 2010-2025 5.2.4 TobraDex Sales Forecast, 2010-2025 5.2.5 Pataday Sales Forecast, 2010-2025 5.2.6 Acular Sales Forecast, 2010-2025 5.2.7 Cravit Sales Forecast, 2010-2025 5.2.8 Zymar Sales Forecast, 2010-2025 6. The Retinal Disorder Market 2010-2025 6.1 The Retinal Disorder Market in 2009 6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market 6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2009 6.1.3 Visudyne was the Second-Highest-Selling Retinal Disorder Drug in 2009 6.1.4 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin 6.2 Retinal Disorder Market Forecasts, 2010-2025 6.2.1 Lucentis Will Drive the Retinal Disorder Market from 2010-2016 6.2.2 Novel Drugs and New Disease Treatments will Drive Growth from 2016-2025 6.2.3 Lucentis Sales Forecast, 2010-2025 6.2.4 Visudyne Sales Forecast, 2010-2025 7. The Dry Eye Market 2010-2025 7.1 The Dry Eye Market in 2009 7.1.1 Restasis is the Only Prescription Drug for Dry Eye in the US 7.1.2 Hyalein: Marketed in Japan and China 7.1.3 Allergan’s Celluvisc is the Third-Best-Selling Dry Eye Brand 7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive 7.2 Dry Eye Market Forecasts, 2010-2025 7.2.1 Increased Sales of Dry Eye Prescription Drugs Predicted from 2009-2013 7.2.2 Growth in the Dry Eye Market Will Moderate After 2013 7.2.3 Restasis Sales Forecast, 2010-2025 7.2.4 Hyalein Sales Forecast, 2010-2025 7.2.5 Celluvisc Sales Forecast, 2010-2025 8. Issues Affecting the Market for Ophthalmic Pharmaceuticals 8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market 8.2 Strengths of the Ophthalmic Pharmaceutical Market 8.2.1 Development of New Drug Delivery Methods and Formulations 8.2.2 Intraocular Injections 8.2.3 Sustained-Release Ocular Implants 8.2.4 Gene Therapy and RNA Interference Technology 8.2.5 New Ophthalmic Therapeutic Applications for Drugs 8.2.6 Development of Neuroprotective Anti-Glaucoma Medications 8.3 Weaknesses of the Ophthalmic Pharmaceutical Market 8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition 8.3.2 Avastin Cannibalising Lucentis' Revenues? 8.4 Opportunities for the Ophthalmic Pharmaceutical Market 8.4.1 The Greying of the World Population 8.4.2 Increasing Prevalence of Diabetes and Unhealthy Lifestyles 8.4.3 Increasing Prevalence of Eye Disorders 8.4.4 Retinal Disorders Will Have the Most-Marked Increases in Prevalence 8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders 8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals 8.5 Threats Facing the Ophthalmic Pharmaceutical Market 8.5.1 Poor Patient Compliance 8.5.2 The Rate of Diagnosis for Many Eye Disorders is Low 9. Ophthalmic Pharmaceutical Country Markets 2010-2025 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009 9.2 Leading Developed Country Ophthalmic Pharmaceutical Markets, 2010-2025 9.2.1 The US Ophthalmic Pharmaceutical Market, 2010-2025 9.2.2 The Japanese Ophthalmic Pharmaceutical Market, 2010-2025 9.2.3 European Ophthalmic Pharmaceutical Markets, 2010-2025 9.3 Emerging Economy Ophthalmic Pharmaceutical Market Forecasts, 2010-2025 9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries 9.3.2 The Chinese Ophthalmic Pharmaceutical Market, 2010-2025 9.3.3 The Indian Ophthalmic Pharmaceutical Market, 2010-2025 10. The Ophthalmic Pharmaceutical R&D Pipeline 10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs 10.2 The Anti-Glaucoma Pipeline 10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development 10.2.2 Taflotan/DE-085 (Santen/Asahi) 10.2.3 Azarga (Alcon) 10.2.4 Anecortave (Alcon) 10.2.5 DNB-001 (Danube) 10.2.6 BVT.28949 (Biovitrum) 10.2.7 OT-730 (Othera) 10.2.8 AL-37807 (Alcon) 10.2.9 PF-4217329 (Pfizer) 10.2.10 QLT's Punctal Plug Delivery Technology 10.2.11 PF-03187207 (NicOx/Pfizer) 10.3 The Ophthalmic Anti-Allergy Pipeline 10.3.1 Bepreve (ISTA/Senju) 10.3.2 FOV1101 (Fovea/CombinatoRx) 10.3.3 DE-103 (Santen) 10.4 The Ophthalmic Anti-Inflammatory Pipeline 10.4.1 T-Pred (ISTA) 10.4.2 AzaSite Plus/ASV-502 (InSite Vision) 10.4.3 Durezol (Senju/Sirion Therapeutics) 10.4.4 Luveniq (Lux Biosciences) 10.4.5 Simulect (Cerimon) 10.4.6 EGP-437 (EyeGate Pharm) 10.5 The Ophthalmic Anti-Infective Pipeline 10.5.1 TobraDex ST (Alcon) 10.5.2 ISV-403/Besifloxacin (Bausch & Lomb) 10.5.3 Moxifloxacin/Dexamethasone (Alcon) 10.5.4 Aganocide (Alcon/NovaBay) 10.6 The Retinal Disease Pipeline 10.6.1 Retinal Diseases Have the Richest Pipeline 10.6.2 Arxxant (Eli Lilly/Alcon/Takeda) 10.6.3 Vitrase/Vitragen (ISTA) 10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer) 10.6.5 Bevasiranib/Cand5 (Opko) 10.6.6 Atacand/TCV-116 (AstraZeneca/Takeda) 10.6.7 Medidur (pSivida/Alimera Sciences/Pfizer) 10.6.8 NT-501 (Neurotech) 10.6.9 Microplasmin (ThromboGenics) 10.6.10 Sustained-Release Brimonidine (Allergan) 10.6.11 RTP801i-14/PF-4523655 (Quark/Pfizer) 10.6.12 AGN-745/SIRNA-027 (Allergan/Merck & Co.) 10.6.13 ATG-3 (CoMentis) 10.6.14 OT-551 (Othera) 10.6.15 Fenretinide (Sirion Therapeutics) 10.6.16 RPE65 Gene Therapy (Targeted Genetics) 10.7 The Dry Eye Pipeline 10.7.1 Prolacria (Inspire/Allergan/Santen) 10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics) 10.7.3 Rebamipide (Otsuka/Acucela) 10.7.4 DE-101/Rivoglitazone (Santen) 10.7.5 Ecabet (ISTA) 10.7.6 SAR 1118 (SARcode) 10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth Stimulators 11. Expert Views from Key Opinion Leaders 11.1 Barrett Katz, MD, MBA, Chief Executive Officer and Chief Medical Officer and Brian Levy, O.D., MSc, Chief Operating Officer, Danube Pharmaceuticals Inc., New York, USA 11.1.1 Neuroprotection is the Key Unmet Need Among Glaucoma Patients 11.1.2 Danube's Pipeline Anti-Glaucoma Medication: DNB-001 11.1.3 Key Threats Facing the Ophthalmic Pharmaceutical Industry 11.1.4 Major Growth Opportunities in the Ophthalmic Pharmaceutical Industry 11.1.5 The Future of the Anti-Glaucoma Market 11.2 Dr Al Reaves, PhD, Senior Vice President of Clinical Development, Othera Pharmaceuticals Inc., Conshohocken, PA, USA 11.2.1 Which Areas of the Ophthalmic Pharmaceutical Market will Experience Greatest Growth? 11.2.2 Othera's Geographic Atrophy Drug: OT-551 11.2.3 How Will Glaucoma be Treated in 2025? 11.2.4 Othera's Neuroprotective Anti-Glaucoma Drug: OT-440 11.2.5 Othera's New Generation Beta Blocker: OT-730 11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments 11.3 Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford, Oxford Eye Hospital, England, UK 11.3.1 Key Unmet Needs 11.3.2 Research and Development 11.3.3 Problems with the Current Use of Ophthalmic Treatments 11.3.4 Challenges in the Development of Ophthalmic Drugs 11.3.5 Complexities Involved in Developing New Ophthalmic Drugs 11.3.6 Growth Opportunities in the Ophthalmic Market 11.3.7 Challenges Facing the Ophthalmic Pharma Industry 11.3.8 Main Regions Offering Growth Potential Worldwide 11.3.9 Needs of Glaucoma Patients 11.3.10 Future Treatments for Glaucoma 11.3.11 Pipeline Developments from a Physician's Perspective 11.3.12 Prospects for Replacing Current Treatments 11.3.13 Novel Treatments for Ophthalmic Diseases 12. Conclusions 12.1 The Ophthalmic Pharmaceutical Market in 2009 12.2 Visiongain's Ophthalmic Pharmaceutical Market Forecast, 2010-2025 12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Market? 12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest? [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Glaucoma Drug Types, 2009 Table 2.2 AMD Drug Types, 2009 Table 2.3 Ophthalmic Allergy Drug Types, 2009 Table 2.4 Ophthalmic Inflammatory Disorder Drug Types, 2009 Table 2.5 Ophthalmic Anti-Infective Drug Types, 2009 Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2009 Table 3.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009 Table 3.3 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2009 Table 3.4 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2016 Table 3.5 World Ophthalmic Pharmaceutical Market Sales Forecast, 2017-2025 Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2010-2016 Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2017-2025 Table 4.1 Leading Anti-Glaucoma Brands, 2009 Table 4.2 World Anti-Glaucoma Market Sales Forecast, 2010-2016 Table 4.3 World Anti-Glaucoma Market Sales Forecast, 2017-2025 Table 4.4 Leading Anti-Glaucoma Brands Sales Forecasts, 2010-2016 Table 4.5 Leading Anti-Glaucoma Brands Sales Forecasts, 2017-2025 Table 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti- Allergy/Inflammatory/Infective Market, 2009 Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands, 2009 Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2010-2016 Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2017-2025 Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecasts, 2010-2016 Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecasts, 2017-2025 Table 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2009 Table 6.2 Leading Retinal Disorder Brands, 2009 Table 6.3 World Retinal Disorder Market Sales Forecast, 2010-2016 Table 6.4 World Retinal Disorder Market Sales Forecast, 2017-2025 Table 6.5 Leading Retinal Disorder Brands Sales Forecast, 2010-2016 Table 6.6 Leading Retinal Disorder Brands Sales Forecast, 2017-2025 Table 7.1 Leading Dry Eye Brands, 2009 Table 7.2 World Dry Eye Market Sales Forecast, 2010-2016 Table 7.3 World Dry Eye Market Sales Forecast, 2017-2025 Table 7.4 Restasis Sales Forecast, 2010-2016 Table 7.5 Restasis Sales Forecast, 2017-2025 Table 7.6 Hyalein Sales Forecast, 2010-2016 Table 7.7 Hyalein Sales Forecast, 2017-2025 Table 7.8 Celluvisc Sales Forecast, 2010-2016 Table 7.9 Celluvisc Sales Forecast, 2017-2025 Table 8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market, 2010-2025 Table 8.2 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2009-2014 Table 8.3 Global Ophthalmic Disorder Prevalence Forecast, 2007-2030 Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009 Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Sales Forecasts, 2010-2016 Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Sales Forecasts, 2017-2025 Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline, 2009 Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline, 2009 Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline, 2009 Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline, 2009 Table 10.5 Key Drugs in the Retinal Disease Pipeline, 2009 Table 10.6 Key Drugs in the Dry Eye Pipeline, 2009 Table 10.7 Key R&D Pipeline Drugs for Other Ophthalmic Indications, 2009 Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2009 Figure 3.2 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2009 Figure 3.3 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2025 Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Shares and Sales Forecasts, 2010-2025 Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2025 Figure 4.1 Leading Anti-Glaucoma Brands, 2009 Figure 4.2 World Anti-Glaucoma Market Sales Forecast, 2010-2025 Figure 4.3 Leading Anti-Glaucoma Brands, 2016 Figure 4.4 Xalatan Sales Forecast, 2010-2025 Figure 4.5 Travatan Sales Forecast, 2010-2025 Figure 4.6 Cosopt Sales Forecast, 2010-2025 Figure 4.7 Lumigan Sales Forecast, 2010-2025 Figure 4.8 Alphagan Sales Forecast, 2010-2025 Figure 4.9 Azopt Sales Forecast, 2010-2025 Figure 4.10 Xalacom Sales Forecast, 2010-2025 Figure 4.11 Trusopt Sales Forecast, 2010-2025 Figure 4.12 Combigan Sales Forecast, 2010-2025 Figure 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti- Allergy/Inflammatory/Infective Market, 2009 Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2010-2025 Figure 5.3 Patanol Sales Forecast, 2010-2025 Figure 5.4 Vigamox Sales Forecast, 2010-2025 Figure 5.5 TobraDex Sales Forecast, 2010-2025 Figure 5.6 Pataday Sales Forecast, 2010-2025 Figure 5.7 Acular Sales Forecast, 2010-2025 Figure 5.8 Cravit Sales Forecast, 2010-2025 Figure 5.9 Zymar Sales Forecast, 2010-2025 Figure 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2009 Figure 6.2 Leading Retinal Disorder Brands, 2009 Figure 6.3 World Retinal Disorder Market Sales Forecast, 2010-2025 Figure 6.4 Lucentis Sales Forecast, 2010-2025 Figure 6.5 Visudyne Sales Forecast, 2010-2025 Figure 7.1 World Dry Eye Market Sales Forecast, 2010-2025 Figure 7.2 Restasis Sales Forecast, 2010-2025 Figure 7.3 Hyalein Sales Forecast, 2010-2025 Figure 7.4 Celluvisc Sales Forecast, 2010-2025 Figure 8.1 Global Population Aged Over 65, 2010-2025 Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2009 and 2025 Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030 Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009 Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2015 Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2020 Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2025 Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Sales Forecasts, 2010-2025 Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Sales Forecasts, 2010-2025 Figure 12.1 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
